


**Beneficial effects of manually assisted chiropractic adjusting instrument
in a rabbit model of osteoarthritis.**

Conesa-Buendía FM¹, Mediero A¹, Fujikawa R², Esbrit P¹, Mulero F³,
Mahillo-Fernández I⁴, Ortega-De Mues A².

¹Bone and Joint Research Unit, Institute of Health Research (IIS-Fundación Jiménez Díaz), ²Madrid College of Chiropractic-Real Centro Universitario Escorial-María Cristina, ³Molecular Imaging Unit, Spanish National Cancer Research Center (CNIO), ⁴Epidemiology and Biostatistics Unit (IIS-Fundación Jiménez Díaz), Madrid, Spain.




Supplementary Figure 1. Images of chiropractic manipulation (CM) carried out with ActivatorV in rabbits. On the left, the true manipulation (TM-OA) performed onto the tibial tubercle of the rabbit right hind limb at a 90° angle from medial to lateral side. On the right, the "false" manipulation (FM-OA) consisting of ActivatorV firing and gently touching the left tibial tubercle.


Supplemental Figure 2. (A,C) Bands chosen to show in the **Figure 6** the representative expression of (A) COX-2, (C) immature form of IL1-B and the corresponding loading controls obtained by Western blot for control, FM-OA and TM-OA conditions. (B, D) Order of the loaded samples in the gel and bands chosen to show in the **Figure 6** the representative expression of (B) TNF- alpha, the active form of (D) IL 1 B and the corresponding loading controls analyzed by western blot for control, FM- OA and TM- OA conditions. The numbers correspond to different animals for each condition. (C control, FM false manipulation, TM true manipulation).

A


COX-2




COX-2







β -actin



β -actin




Supplementary Figure 2

BTNF- α TNF- α  β -actin β -actin


Supplementary Figure 2

C

IL1- β (immature form)



β -actin




Supplementary Figure 2

D

IL1- β
(active form)



β -actin




Supplementary Figure 2


Supplementary Figure 3. Bands chosen to show in the **Figure 7** the representative expression of **(A)** MMP-3, **(B)** COL VI, **(C)** VEGF-164 and the corresponding loading controls, obtained by Western blot for control, FM-OA and TM-OA conditions.

A

MMP-3




β -actin



Supplementary Figure 3

B




Supplementary Figure 3

C

VEGF-164



β -actin



Supplementary Figure 3

Supplementary Table 1. Numerical data of the different parameters studied and presented as bar graphs in the text.

<i>SUBCHONDRAL BONE</i>			
<i>Parameters</i>	<i>CONTROL (n=6)</i>	<i>FM-OA (n=10)</i>	<i>TM-OA (n=10)</i>
<i>ALP (% positive area)</i>	9.6 (2.29)	27.3 (15.6)**	16.6 (4.20)*, #
<i>Osteoclasts N/mm² (TRAP % positive area)</i>	12.0 (5.00)	34.5 (12.2)***	28.5 (7.75)**, ###
<i>RANKL (% positive area)</i>	1.36 (3.87)	24.9 (17.6)**	12.0 (6.08)**, #
<i>OPG (% positive area)</i>	1.31 (1.22)	15.3 (6.89)**	8.66 (8.22)**, #
<i>RANKL/OPG Ratio</i>	1.04 (0.48)	1.62 (0.78)*	1.39 (0.12)*, #
<i>CARTILAGE</i>			
<i>Parameters</i>	<i>CONTROL (n=6)</i>	<i>FM-OA (n=10)</i>	<i>TM-OA (n=10)</i>
<i>Macroscopic damage Score (AU)</i>	0.00 (0.00)	3.00 (1.00)**	1.50 (1.00)**, #
<i>Mankin's Score (AU)</i>	0.00 (0.81)	7.50 (4.50)***	4.50 (4.25)***, #
<i>SYNOVIAL MEMBRANE</i>			
<i>Krenn' Score Total (AU)</i>	0.00 (0.00)	4.38 (1.69)**	3.50 (1.25)**, #
<i>Lining Hipertrophy (AU)</i>	0.00 (0.38)	1.19 (0.44)**	0.94 (0.25)**, #
<i>Synovial Matrix (AU)</i>	0.00 (0.38)	1.62 (0.94)**	1.94 (0.91)**
<i>Inflammatory Infiltrate (AU)</i>	0.00 (0.00)	1.12 (0.78)**	0.50 (0.75)*, #
<i>RAM11 (% positive area)</i>	0.11 (0.10)	0.82 (0.55)**	0.35 (0.41)*, #
<i>COX-2 Expression (AU)</i>	1.00 (0.00)	5.45 (1.00)*	2.55 (0.27)*, #
<i>TNFα Expression (AU)</i>	1.00 (0.00)	1.31 (0.18)**	1.03 (0.27)#
<i>IL1b Expression-Immature Form (AU)</i>	1.00 (0.00)	2.46 (0.78)*	1.52 (0.24)*, #
<i>Il1b Expression- Active Form (AU)</i>	1.00 (0.00)	1.35 (0.29)*	0.68 (0.20)**, ###
<i>MMP-3 Expression (AU)</i>	1.00 (0.00)	1.52 (0.21)**	1.13 (0.20)##
<i>COL VI Expression (AU)</i>	1.00 (0.00)	2.19 (0.85)*	1.45 (0.35)#

<i>VEGF-164 Expression (AU)</i>	1.00 (0.00)	1.72 (0.43)**	1.21 (0.45)**,#
<i>CD31 (% positive area)</i>	0.02 (0.04)	0.97 (0.69)**	0.32 (0.13)**,##

Values are median (IQR). *p<0.05, **p<0.01, ***p<0.001 vs healthy control, #p<0.05, ##p<0.01, ###p<0.001 vs FM-OA. P values were obtained using non-parametric Kruskal-Wallis test with a post-hoc correction (Dunn's procedure) for comparison among multiple groups, and Mann-Whitney U test for comparison between two groups.